Earnings Feed
Start Free
Home/Filings/4/0001144204-14-050902
4//SEC Filing

INTERCEPT PHARMACEUTICALS INC 4

Accession 0001144204-14-050902

CIK 0001270073operating
View on SEC.govCompany Profile

Filed

Aug 14, 8:00 PM ET

Accepted

Aug 15, 9:00 PM ET

Size

54.9 KB

Accession

0001144204-14-050902

Insider Transaction Report

Form 4
Period: 2014-08-12
INTERCEPT PHARMACEUTICALS INCICPT
Regan Daniel Paul
Chief Commerical Officer
Transactions
  • Sale

    Common Stock

    2014-08-12$306.91/sh−100$30,691→ 9,234 total
  • Exercise/Conversion

    Common Stock

    2014-08-12$37.69/sh+8,124$306,194→ 9,534 total
  • Sale

    Common Stock

    2014-08-12$305.38/sh−200$61,077→ 9,334 total
  • Sale

    Common Stock

    2014-08-12$310.10/sh−500$155,052→ 8,734 total
  • Sale

    Common Stock

    2014-08-12$311.88/sh−500$155,943→ 8,234 total
  • Sale

    Common Stock

    2014-08-12$312.77/sh−200$62,555→ 8,034 total
  • Sale

    Common Stock

    2014-08-12$313.84/sh−800$251,072→ 7,234 total
  • Sale

    Common Stock

    2014-08-12$314.93/sh−600$188,955→ 6,634 total
  • Sale

    Common Stock

    2014-08-12$316.62/sh−200$63,324→ 6,434 total
  • Sale

    Common Stock

    2014-08-12$317.70/sh−400$127,082→ 6,034 total
  • Sale

    Common Stock

    2014-08-12$319.47/sh−400$127,787→ 5,634 total
  • Sale

    Common Stock

    2014-08-12$321.44/sh−200$64,288→ 5,434 total
  • Sale

    Common Stock

    2014-08-12$322.92/sh−100$32,292→ 5,334 total
  • Sale

    Common Stock

    2014-08-12$326.03/sh−100$32,603→ 5,234 total
  • Sale

    Common Stock

    2014-08-12$327.89/sh−300$98,366→ 4,934 total
  • Sale

    Common Stock

    2014-08-12$329.59/sh−594$195,777→ 4,340 total
  • Sale

    Common Stock

    2014-08-12$330.91/sh−206$68,167→ 4,134 total
  • Sale

    Common Stock

    2014-08-12$331.92/sh−200$66,384→ 3,934 total
  • Sale

    Common Stock

    2014-08-12$335.01/sh−100$33,502→ 3,834 total
  • Sale

    Common Stock

    2014-08-12$336.47/sh−200$67,293→ 3,634 total
  • Sale

    Common Stock

    2014-08-12$337.17/sh−100$33,717→ 3,534 total
  • Sale

    Common Stock

    2014-08-12$341.20/sh−300$102,362→ 3,234 total
  • Sale

    Common Stock

    2014-08-12$342.05/sh−300$102,614→ 2,934 total
  • Sale

    Common Stock

    2014-08-12$343.80/sh−800$275,039→ 2,134 total
  • Sale

    Common Stock

    2014-08-12$344.73/sh−500$172,366→ 1,634 total
  • Sale

    Common Stock

    2014-08-12$346.68/sh−224$77,656→ 1,410 total
  • Exercise/Conversion

    Option to Purchase Common Stock

    2014-08-12−8,124→ 101,875 total
    Exercise: $37.69Exp: 2023-03-04→ Common Stock (8,124 underlying)
Footnotes (23)
  • [F1]The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2014.
  • [F10]This transaction was executed in multiple trades at prices ranging from $317.58 to $317.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F11]This transaction was executed in multiple trades at prices ranging from $319.01 to $319.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F12]This transaction was executed in multiple trades at prices ranging from $321 to $321.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F13]This transaction was executed in multiple trades at prices ranging from $327.29 to $328.195. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F14]This transaction was executed in multiple trades at prices ranging from $329.11 to $330. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F15]This transaction was executed in multiple trades at prices ranging from $330.44 to $331.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F16]This transaction was executed in multiple trades at prices ranging from $331.8 to $332.1. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F17]This transaction was executed in multiple trades at prices ranging from $335 to $335.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F18]This transaction was executed in multiple trades at prices ranging from $336.16 to $336.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F19]This transaction was executed in multiple trades at prices ranging from $340.94 to $341.66. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F2]The remaining shares underlying this option vest on a pro rata monthly basis through March 4, 2017, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan.
  • [F20]This transaction was executed in multiple trades at prices ranging from $341.97 to $342.155. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F21]This transaction was executed in multiple trades at prices ranging from $343.23 to $344.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F22]This transaction was executed in multiple trades at prices ranging from $344.275 to $345.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F23]This transaction was executed in multiple trades at prices ranging from $346.4 to $346.8. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F3]This transaction was executed in multiple trades at prices ranging from $305.32 to $305.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F4]This transaction was executed in multiple trades at prices ranging from $309.7 to $310.63. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F5]This transaction was executed in multiple trades at prices ranging from $311.27 to $312.165. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F6]This transaction was executed in multiple trades at prices ranging from $312.32 to $313.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F7]This transaction was executed in multiple trades at prices ranging from $313.43 to $314.265. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F8]This transaction was executed in multiple trades at prices ranging from $314.54 to $315.38. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F9]This transaction was executed in multiple trades at prices ranging from $316.195 to $317.045. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Documents

1 file

Issuer

INTERCEPT PHARMACEUTICALS INC

CIK 0001270073

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001270073

Filing Metadata

Form type
4
Filed
Aug 14, 8:00 PM ET
Accepted
Aug 15, 9:00 PM ET
Size
54.9 KB
View on SEC.gov